Healthy Volunteer
Conditions
Brief summary
This is a phase 1, single subcutaneous dose study to evaluate safety and pharmacokinetics of 2 different dupilumab drug product in healthy volunteers. The duration per participant is up to 11 weeks.
Detailed description
Duration per participant is up to 11 weeks.
Interventions
Injection solution, subcutaneous
Sponsors
Regeneron Pharmaceuticals
Sanofi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female participants, between 18 and 65 years of age, inclusive. * Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). * Body weight between 70.0 and 90.0 kg, inclusive. * Having given written informed consent prior to undertaking any study-related procedure.
Exclusion criteria
* Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness. * Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month). * Blood donation or collection totaling more than 250 mL (including collections during study screening) within 2 months before inclusion on Day -1. * Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥20 mmHg within 3 minutes when changing from supine to standing position. * History of light-headedness or syncope during blood collection or injection of medications. * Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician. * History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis). * If female, pregnancy (defined as positive β-human chorionic gonadotropin blood test) or breast-feeding. * Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness. * Participation in any clinical research study evaluating another investigational drug or therapy within 30 days or 5 elimination half-lives of the respective investigational drug, whichever is longer, of the inclusion visit. * Any participant who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum serum concentration observed: Cmax | Up to Day 57 |
| Time to reach Cmax (tmax) | Up to Day 57 |
| Area under the serum concentration versus time curve from time zero to the real time of last measurable concentration (AUClast) | Up to Day 57 |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of treatment-emergent adverse events (TEAEs) | Up to Day 57 |
| Incidence of anti-dupilumab antibodies (ADA) | Up to Day 57 |
Countries
United States
Outcome results
None listed